Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer.
IORT
Intraoperative Radiation Therapy
Pancreatic Cancer
Portal Vein Thrombosis
Superior Mesenteric Vein Thrombosis
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: Netherlands
ID NLM: 9706084
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
10
04
2023
accepted:
29
07
2023
medline:
22
11
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Portal vein and superior mesenteric vein thrombosis (PVT/SMVT) are potentially morbid complications of radiation dose-escalated local therapy for pancreatic cancer. We retrospectively reviewed records for patients treated with and without intraoperative radiation (IORT) to identify risk factors for PVT/SMVT. Ninety-six patients with locally advanced or borderline resectable pancreatic adenocarcinoma received neoadjuvant therapy followed by surgical exploration from 2009 to 2014. Patients at risk for close or positive surgical margins received IORT boost to a biologically effective dose (BED10) > 100. Prognostic factors for PVT/SMVT were evaluated using competing risks regression. Median follow-up was 79 months for surviving patients. Fifty-six patients (58%) received IORT. Twenty-nine patients (30%) developed PVT/SMVT at a median time of 18 months. On univariate competing risks regression, operative blood loss and venous repair with a vascular interposition graft, but not IORT dose escalation or diabetes history, were significantly associated with PVT/SMVT. The development of thrombosis in the absence of recurrence was significantly associated with a longstanding diabetes history, post-neoadjuvant treatment CA19-9, and operative blood loss. All 4 patients who underwent both IORT and vascular repair with a graft developed PVT/SMVT. PVT/SMVT in the absence of recurrence is not associated with significantly worsened overall survival but led to frequent medical interventions. Approximately 30% of patients who underwent neoadjuvant chemoradiation for PDAC developed PVT/SMVT a median of 18 months following surgery. This was significantly associated with venous reconstruction with vascular grafts, but not with escalating radiation dose. PVT/SMVT in the absence of recurrence was associated with significant morbidity.
Identifiants
pubmed: 37578568
doi: 10.1007/s11605-023-05796-5
pii: S1091-255X(24)00052-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2464-2473Informations de copyright
© 2023. The Society for Surgery of the Alimentary Tract.
Références
Cancer Stat Facts: Pancreatic Cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program.
Gillen S, Schuster T, Büschenfelde CM, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 7 (4). Aug 2022 https://pubmed.ncbi.nlm.nih.gov/20422030/
Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012 ;19(5):1644–62. Aug 29, 2022 https://pubmed.ncbi.nlm.nih.gov/22012027/
doi: 10.1245/s10434-011-2110-8
pubmed: 22012027
Conroy T, Castan F, Lopez A, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol 2022 2022 Sep, https://jamanetwork.com/journals/jamaoncology/fullarticle/2795978
Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019 111(8):782–94. Sep 2022, https://pubmed.ncbi.nlm.nih.gov/31086963/
doi: 10.1093/jnci/djz073
pubmed: 31086963
pmcid: 6695305
Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 2022 ;40(11):1220–30. Aug 30 2022, https://pubmed.ncbi.nlm.nih.gov/35084987/
doi: 10.1200/JCO.21.02233
pubmed: 35084987
Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019 5(7):1020–7. Sep 2022, https://pubmed.ncbi.nlm.nih.gov/31145418/
doi: 10.1001/jamaoncol.2019.0892
pubmed: 31145418
pmcid: 6547247
Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018 ;4(7):963–9. Sep 2022, https://pubmed.ncbi.nlm.nih.gov/29800971/
doi: 10.1001/jamaoncol.2018.0329
pubmed: 29800971
pmcid: 6145728
Katz MHG, Shi Q, Meyers J, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol 2022 Sep 2022, https://jamanetwork.com/journals/jamaoncology/fullarticle/2794338
Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021 21 (1). Sep 2022, https://pubmed.ncbi.nlm.nih.gov/33757440/
Krishnan S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys 2016;94(4):755–65.
doi: 10.1016/j.ijrobp.2015.12.003
pubmed: 26972648
Zaorsky NG, Lehrer EJ, Handorf E, Meyer JE. Dose escalation in stereotactic body radiation therapy for pancreatic cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 2019;42(1):46–55.
doi: 10.1097/COC.0000000000000472
Rossi G, Simoni N, Paiella S, et al. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Front Oncol 2021;11.
Bertholet J, Hunt A, Dunlop A, et al. Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. Clin Transl Radiat Oncol 2019;16:21–7.
pubmed: 30911688
pmcid: 6416653
Courtney PT, Paravati AJ, Atwood TF, et al. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2021;110(4):1003–12.
doi: 10.1016/j.ijrobp.2021.02.008
pubmed: 33571625
Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: Techniques and results. Radiation Oncology. 2019;14(1).
Kaučić H, Kosmina D, Schwarz D, et al. Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study. Cancers (Basel) 2022;14(11):2688.
doi: 10.3390/cancers14112688
pubmed: 35681668
Harrison JM, Wo JY, Ferrone CR, et al. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Ann Surg Oncol 2020;27(5):1400–6.
doi: 10.1245/s10434-019-08084-2
pubmed: 31758284
Jin L, Shi N, Ruan S, et al. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiat Oncol 2020;15 (1). Sep 2022, https://pubmed.ncbi.nlm.nih.gov/32272945/
Keane FK, Wo JY, Ferrone CR, et al. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol 2018 ;41(6):607–12. Sep 2022, https://pubmed.ncbi.nlm.nih.gov/27740973/
doi: 10.1097/COC.0000000000000336
pubmed: 27740973
Parikh PJ. Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.gov [Internet]. 2018 Aug 30 2022, https://clinicaltrials.gov/ct2/show/NCT03621644
Parikh PJ, Lee P, Low D, et al. Stereotactic MR-Guided On-Table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Locally Advanced Pancreatic Cancer: Primary Endpoint Outcomes of a Prospective Phase II Multi-Center International Trial. Int J Radiat Oncol Biol Phys 2022;114(5):8.
doi: 10.1016/j.ijrobp.2022.09.010
Gawlas I, Epelboym I, Winner M, et al. Short-term but not long-term loss of patency of venous reconstruction during pancreatic resection is associated with decreased survival. J Gastrointest Surg [Internet] 2014 18(1):75–82. Aug 29 2022, https://pubmed.ncbi.nlm.nih.gov/24114682/
doi: 10.1007/s11605-013-2375-2
pubmed: 24114682
Clark W, Silva M, Donn N, et al. Targeting early deaths following pancreaticoduodenectomy to improve survival. J Gastrointest Surg 2012 16(10):1869–74. Aug 29 2022, https://pubmed.ncbi.nlm.nih.gov/22875597/
doi: 10.1007/s11605-012-1958-7
pubmed: 22875597
Glebova NO, Hicks CW, Piazza KM, et al. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. Journal of Vascular Surgery. 2015. p. 424–33.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40(5):373–83.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Cai S, Hong TS, Goldberg SI, et al. Updated Long-Term Outcomes and Prognostic Factors for Patients With Unresectable Locally Advanced Pancreatic Cancer Treated With Intraoperative Radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer 2013 ; 119(23):4196. Aug 2022, /pmc/articles/PMC4403862/
doi: 10.1002/cncr.28329
pubmed: 24006012
Salei A, El Khudari H, McCafferty BJ, Varma RK. Portal Interventions in the Setting of Venous Thrombosis or Occlusion. Radiographics 2022 ; 42 (6):1690–704. Mar 2023, https://pubs.rsna.org/doi/10.1148/rg.220020
doi: 10.1148/rg.220020
pubmed: 36190859
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. Ann Surg 2015;261(1):12. Aug 29 2022, /pmc/articles/PMC4349683/
doi: 10.1097/SLA.0000000000000867
pubmed: 25599322
Lacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. Journal of Clinical Oncology 2009 27 (11):1806 Aug 29 2022, pmc/articles/PMC2668706/
doi: 10.1200/JCO.2008.17.7188
Kluger MD, Epelboym I, Schrope BA, et al. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Annals of Surgical Oncology 2015 23 (5):1736–43. Aug 29 2022, https://link.springer.com/article/10.1245/s10434-015-5034-x
doi: 10.1245/s10434-015-5034-x
pubmed: 26714959
Martin RCG, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (Stage III) pancreatic adenocarcinoma patients with irreversible electroporation safety and efficacy. Ann Surg 2015 262 (3):486–92. Aug 29 ,2022 https://journals.lww.com/annalsofsurgery/Fulltext/2015/09000/Treatment_of_200_Locally_Advanced__Stage_III_.10.aspx
doi: 10.1097/SLA.0000000000001441
pubmed: 26258317
Bell EJ, Folsom AR, Lutsey PL, et al. Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016 111:10–8. Sep 12 2022 , https://pubmed.ncbi.nlm.nih.gov/26612139/
doi: 10.1016/j.diabres.2015.10.019
pubmed: 26612139
Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med 2016 28: 52–8 Sep 12 2022 https://pubmed.ncbi.nlm.nih.gov/26507303/
doi: 10.1016/j.ejim.2015.10.001
pubmed: 26507303
Raskob GE, Wendelboe AM, Campbell J, et al. Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population. Journal of Thrombosis and Haemostasis 2022; 20 (10):2366.
doi: 10.1111/jth.15818
pubmed: 35830203
pmcid: 9804159